Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Dendreon | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Dendreon

Revenues down 12% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Dendreon

4Q Revenues: $74.8 million (-12%)

4Q Loss: $88.7 million (loss of $38.7 million 4Q12)

FY Revenues: $283.7 million (-13%)

FY Loss: $296.8 million (loss of $393.6 million FY12)

Comments: The company added 31 new accounts for PROVENGE in the quarter and implemented a new commercial model. The company will make PROVENGE available in Europe through Centers of Excellence using CMO PharmaCell, beginning with Germany and the UK. Royalty and other revenues were down to $7 million in the quarter, from $38 million in 4Q12.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters